Tag Archives: india

FDA Finding Fuels Indian Crackdown on Sub-standard Drugs

By Guest Blogger | Published: July 27, 2011
By Mangesh Sai, Asia Correspondent. A routine monthly inspection carried out by the Food and Drugs Administration (FDA) authorities in the state of Maharashtra, India, last month noted an increase in the number of sub-standard drug samples raising apprehensions about the availability of safe and genuine drugs in the state. Officials pointed out that 26 drug samples [...]
Posted in Anti-counterfeiting, Global, Guest Blog, IP, Safety | Also tagged , , , | Leave a comment

Indian Government Proposes Ban on Physician Gifts

By Ben Comer | Published: June 6, 2011
India’s Department of Pharmaceuticals released a 14-page “voluntary code” for drug marketers, which includes a strict ban on gifts to prescribers, among other things. The code, which is open for public comment until June 30th, states that “no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to persons qualified to prescribe” [...]
Posted in Advertising, Emerging Markets, Global, Marketing, Medical Education, Strategy | Also tagged , , , , , | Leave a comment

New Decade, New Agenda for Pharma

By Guest Blogger | Published: January 12, 2011
A new track for nonprofits, product diversification and the rise of the emerging markets —  Audrey S. Erbes reports on some of the takeaways from this week’s JP Morgan Healthcare Conference. There were some surprising changes in the format of the 29th Annual JP Morgan Healthcare Conference, the world’s premier health care industry investment meeting which [...]
Posted in Emerging Markets, Guest Blog, R&D | Also tagged , , , , | Leave a comment

Fixing Biotech's Broken Business Model

By Julian Upton | Published: December 22, 2010
Despite some notable successes, the global biotech industry has fallen short of expectations. Strategic collaborations have been on the increase, but there is now a need for more co-operation using new collaboration models, writes Jo Pisani. The current business model on which biotech has relied is flawed. Due to poor rates of return, investment has dried [...]
Posted in Biotech, Deals, Emerging Markets, Europe, Global, Guest Blog, R&D | Also tagged , , , , , , , | Leave a comment

Abbott Shells Out $3.7 Billion for Piramal

By Oriana Schwindt | Published: May 26, 2010
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment